Tests Tb-PSMA radionuclide before surgery for locally advanced prostate cancer
Tests Tb-PSMA radionuclide treatment before prostate removal in men with prostate cancer.
Plain-language title generated from the registry record
Registry title: Tb-PSMA-I&T Radionuclide Before Radical Prostatectomy in Patients With Locally Advanced Prostate Cancer - TbeforePROST Trial.
Key facts
- Where
- Petah Tikva, IsraelSee the site
- Phase
- Phase 1/2
Where in Israel
- Beilinson HospitalPetah Tikva, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Rabin Medical Center
- Trial code
- NCT07208240
- Record updated
- 6 October 2025
- Original description
This is a multi-disciplinary collaboration between urologists, oncologists and nuclear medicine physicians from Beilinson hospital at Rabin Medical Center to address the major therapeutic challenge of locally advanced prostate cancer. Our aim is to evaluate the use of a novel treatment (Tb-PSMA) prior to the surgical removal of the prostate. This treatment has already shown initial promising results in patients with metastatic prostate cancer but has never been tested for locally advanced disease before surgery.Read full original descriptionShow less
Tb-PSMA-I&T Radionuclide Neo-Adjuvant Treatment in Patients With Locally Advanced Prostate Cancer Before Radical Prostatectomy: TbeforePROST Trial.
This is a multi-disciplinary collaboration between urologists, oncologists and nuclear medicine physicians from Beilinson hospital at Rabin Medical Center to address the major therapeutic challenge of locally advanced prostate cancer. Our aim is to evaluate the use of a novel treatment (Tb-PSMA) prior to the surgical removal of the prostate. This treatment has already shown initial promising results in patients with metastatic prostate cancer but has never been tested for locally advanced disease before surgery.
Inclusion: Male aged 18 years and older; Patients with high-risk localized prostate cancer (cT3/4 and/or Gleason score ≥ eight and/or prostate biopsy or PSA ≥ 20 ng/dl); High PSMA expression was confirmed according to PROMISE V2 8; Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status score of 1 or lower and a life expectancy of > 10 years.
Exclusion: usage of nephrotoxic drugs; distant metastatic disease; Platelet count lower than 150×103/µl; white blood cell count lower than 4×103/µl,; haemoglobin concentration lower than 12mg/dl; albumin concentration lower than 3.5 g/dl; glomerular filtration rate (GFR) lower than 40 mL/min.